ImmunityBio Announces Breakthrough Findings: ANKTIVA® Reverses Lymphopenia and Extends Survival in Advanced Lung Cancer Patients

Reuters09-08

ImmunityBio Announces Breakthrough Findings: ANKTIVA® Reverses Lymphopenia and Extends Survival in Advanced Lung Cancer Patients

ImmunityBio, Inc. has announced significant findings from the Phase 2 QUILT-3.055 study, highlighting the potential of ANKTIVA® (nogapendekin alfa inbakicept-pmln) in reversing lymphopenia and extending overall survival in patients with advanced non-small cell lung cancer (NSCLC) resistant to checkpoint inhibitor therapy. The study results, which were already presented at the IASLC 2025 World Conference on Lung Cancer in Barcelona, reveal that ANKTIVA successfully reversed lymphopenia in 60% of participants, suggesting a promising approach to improving median overall survival. The Phase 3 ResQ201A trial is currently evaluating the combination of ANKTIVA and tislelizumab against docetaxel in second-line NSCLC patients. Interested patients can find more details at CSSIFM.org.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250908610169) on September 08, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2565681802?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-08 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2565681802","market":"us","top_or_hot":-1,"title":"ImmunityBio Announces Breakthrough Findings: ANKTIVA® Reverses Lymphopenia and Extends Survival in Advanced Lung Cancer Patients","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ImmunityBio Announces Breakthrough Findings: ANKTIVA® Reverses Lymphopenia and Extends Survival in Advanced Lung Cancer Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IBRX\">ImmunityBio, Inc.</a> has announced significant findings from the Phase 2 QUILT-3.055 study, highlighting the potential of ANKTIVA® (nogapendekin alfa inbakicept-pmln) in reversing lymphopenia and extending overall survival in patients with advanced non-small cell lung cancer (NSCLC) resistant to checkpoint inhibitor therapy. The study results, which were already presented at the IASLC 2025 World Conference on Lung Cancer in Barcelona, reveal that ANKTIVA successfully reversed lymphopenia in 60% of participants, suggesting a promising approach to improving median overall survival. The Phase 3 ResQ201A trial is currently evaluating the combination of ANKTIVA and tislelizumab against docetaxel in second-line NSCLC patients. Interested patients can find more details at CSSIFM.org.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250908610169) on September 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmunityBio Announces Breakthrough Findings: ANKTIVA® Reverses Lymphopenia and Extends Survival in Advanced Lung Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunityBio Announces Breakthrough Findings: ANKTIVA® Reverses Lymphopenia and Extends Survival in Advanced Lung Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-08 20:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ImmunityBio Announces Breakthrough Findings: ANKTIVA® Reverses Lymphopenia and Extends Survival in Advanced Lung Cancer Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IBRX\">ImmunityBio, Inc.</a> has announced significant findings from the Phase 2 QUILT-3.055 study, highlighting the potential of ANKTIVA® (nogapendekin alfa inbakicept-pmln) in reversing lymphopenia and extending overall survival in patients with advanced non-small cell lung cancer (NSCLC) resistant to checkpoint inhibitor therapy. The study results, which were already presented at the IASLC 2025 World Conference on Lung Cancer in Barcelona, reveal that ANKTIVA successfully reversed lymphopenia in 60% of participants, suggesting a promising approach to improving median overall survival. The Phase 3 ResQ201A trial is currently evaluating the combination of ANKTIVA and tislelizumab against docetaxel in second-line NSCLC patients. Interested patients can find more details at CSSIFM.org.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250908610169) on September 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nNDL5XX0ZJ:1","article_id":"2565681802","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2565681802","pubTimestamp":1757334700,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ImmunityBio Announces Breakthrough Findings: ANKTIVA Reverses Lymphopenia and Extends Survival in Advanced Lung Cancer Patients. ImmunityBio, Inc. has announced significant findings from the Phase 2 QUILT-3.055 study, highlighting the potential of ANKTIVA  in reversing lymphopenia and extending overall survival in patients with advanced non-small cell lung cancer  resistant to checkpoint inhibitor therapy. The study results, which were already presented at the IASLC 2025 World Conference on Lung Cancer in Barcelona, reveal that ANKTIVA successfully reversed lymphopenia in 60% of participants, suggesting a promising approach to improving median overall survival. The Phase 3 ResQ201A trial is currently evaluating the combination of ANKTIVA and tislelizumab against docetaxel in second-line NSCLC patients. Interested patients can find more details at CSSIFM.org.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to pr","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IBRX":"ImmunityBio, Inc."},"translate_title":"ImmunityBio宣布突破性发现：ANKTIVA®逆转晚期肺癌患者淋巴细胞减少并延长生存期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":0.9},"content_text":"ImmunityBio Announces Breakthrough Findings: ANKTIVA® Reverses Lymphopenia and Extends Survival in Advanced Lung Cancer Patients\n    \n\nImmunityBio, Inc. has announced significant findings from the Phase 2 QUILT-3.055 study, highlighting the potential of ANKTIVA® (nogapendekin alfa inbakicept-pmln) in reversing lymphopenia and extending overall survival in patients with advanced non-small cell lung cancer (NSCLC) resistant to checkpoint inhibitor therapy. The study results, which were already presented at the IASLC 2025 World Conference on Lung Cancer in Barcelona, reveal that ANKTIVA successfully reversed lymphopenia in 60% of participants, suggesting a promising approach to improving median overall survival. The Phase 3 ResQ201A trial is currently evaluating the combination of ANKTIVA and tislelizumab against docetaxel in second-line NSCLC patients. Interested patients can find more details at CSSIFM.org.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250908610169) on September 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2565681802","isCrawlerRequest":true}